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Abstract: AIMS Arrhythmogenic right ventricular cardiomyopathy (ARVC) is associated with life-
threatening ventricular arrhythmia and progressive ventricular dysfunction. Previous studies suggested
that sex hormones play an important role in the onset and prognosis of ARVC. This study aimed to
investigate the role of testosterone in predicting major adverse cardiac events in the Chinese ARVC co-
hort. METHODS AND RESULTS Ninety-nine ARVC patients (median age, 40 years; 70.7% male) and
96 healthy controls (median age, 41 years; 62.5% male) were enrolled. The circulating levels of testos-
terone were measured by enzyme-linked immunosorbent assays (ELISA). The median follow-up time of
all ARVC male patients was 17 months (interquartile range/IQR 9-29). Cox proportional hazards re-
gression was used to analyse the effect of plasma testosterone and other well-described risk factors on
malignant arrhythmic events in male ARVC patients. The male ARVC patients had significantly elevated
levels of total testosterone [TT, 6.390 (4.438-8.768) ng/mL vs. 3.617 (2.073-4.479) ng/mL, P < 0.0001,
data shown as the median with IQR], bioavailable testosterone [BT, 4.11 (1.990-6.545) ng/mL vs. 1.32
(0.7965-2.0350) ng/mL, P < 0.0001, median with IQR], and free testosterone [FT, 0.2055 (0.1000-0.4073)
ng/mL vs. 0.0768 (0.0405-0.1105) ng/mL, P < 0.0001, median with IQR] than healthy male volunteer,
whereas no differences were observed among female counterparts. There was no significant correlation
between the baseline clinical characteristics and testosterone levels in male ARVC patients (Spearman’s
correlation test, P > 0.05). During the follow-up, the levels of testosterone were higher in male patients
who experienced malignant arrhythmic events (N = 22) than in those who did not (N = 25) [TT, 9.034
(7.222-15.370) ng/mL vs. 4.633 (3.363-6.375) ng/mL, P < 0.001; BT, 7.485 (2.070-9.163) ng/mL vs.
3.300 (1.685-4.690) ng/mL, P < 0.05; FT, 0.453 (0.221-0.758) ng/mL vs. 0.161 (0.075-0.337) ng/mL P
< 0.05, data expressed as median (IQR) and adjusted by Dunn’s multiple comparisons test], whereas
such distinction was not observed among patients with significant structural progression events (N =
16). Through multivariable adjustments, the Cox regression analysis showed the level of plasma total
testosterone (HR = 1.325, 95% confidence interval = 1.171-1.498, P < 0.001) was an independent predic-
tor for malignant arrhythmic events. CONCLUSIONS The levels of plasma testosterone in ARVC male
patients are higher than those in healthy males. Testosterone level, without relation to the baseline car-
diac function and future significant structural progression events, is a strong predictor of future adverse
arrhythmic events in male patients with ARVC. Therefore, our results suggest that testosterone may be
a useful biomarker in arrhythmic risk prediction in the ARVC.
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Abstract
Aims Arrhythmogenic right ventricular cardiomyopathy (ARVC) is associated with life-threatening ventricular arrhythmia and
progressive ventricular dysfunction. Previous studies suggested that sex hormones play an important role in the onset and
prognosis of ARVC. This study aimed to investigate the role of testosterone in predicting major adverse cardiac events in
the Chinese ARVC cohort.
Methods and results Ninety-nine ARVC patients (median age, 40 years; 70.7% male) and 96 healthy controls (median age,
41 years; 62.5% male) were enrolled. The circulating levels of testosterone were measured by enzyme-linked immunosorbent
assays (ELISA). The median follow-up time of all ARVC male patients was 17 months (interquartile range/IQR 9–29). Cox pro-
portional hazards regression was used to analyse the effect of plasma testosterone and other well-described risk factors on
malignant arrhythmic events in male ARVC patients. The male ARVC patients had significantly elevated levels of total testos-
terone [TT, 6.390 (4.438–8.768) ng/mL vs. 3.617 (2.073–4.479) ng/mL, P < 0.0001, data shown as the median with IQR], bio-
available testosterone [BT, 4.11 (1.990–6.545) ng/mL vs. 1.32 (0.7965–2.0350) ng/mL, P < 0.0001, median with IQR], and free
testosterone [FT, 0.2055 (0.1000–0.4073) ng/mL vs. 0.0768 (0.0405–0.1105) ng/mL, P < 0.0001, median with IQR] than
healthy male volunteer, whereas no differences were observed among female counterparts. There was no significant correla-
tion between the baseline clinical characteristics and testosterone levels in male ARVC patients (Spearman’s correlation test,
P > 0.05). During the follow-up, the levels of testosterone were higher in male patients who experienced malignant arrhyth-
mic events (N = 22) than in those who did not (N = 25) [TT, 9.034 (7.222–15.370) ng/mL vs. 4.633 (3.363–6.375) ng/mL,
P < 0.001; BT, 7.485 (2.070–9.163) ng/mL vs. 3.300 (1.685–4.690) ng/mL, P < 0.05; FT, 0.453 (0.221–0.758) ng/mL vs.
0.161 (0.075–0.337) ng/mL P < 0.05, data expressed as median (IQR) and adjusted by Dunn’s multiple comparisons test],
whereas such distinction was not observed among patients with significant structural progression events (N = 16). Through
multivariable adjustments, the Cox regression analysis showed the level of plasma total testosterone (HR = 1.325, 95% confi-
dence interval = 1.171–1.498, P < 0.001) was an independent predictor for malignant arrhythmic events.
Conclusions The levels of plasma testosterone in ARVC male patients are higher than those in healthy males. Testosterone
level, without relation to the baseline cardiac function and future significant structural progression events, is a strong predictor
of future adverse arrhythmic events in male patients with ARVC. Therefore, our results suggest that testosterone may be a
useful biomarker in arrhythmic risk prediction in the ARVC.
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Introduction
Arrhythmogenic cardiomyopathy is an inherited disease that
is associated with life-threatening ventricular arrhythmias,
particularly during adolescence and early adulthood. It is
one of the leading causes of sudden cardiac death in the
young and athletes.1 This disease primarily affects the right
ventricle (RV), and therefore, it is often called arrhythmo-
genic right ventricular cardiomyopathy (ARVC). In advanced
stages of the disease, the left ventricle (LV) may also be in-
volved, resulting in progressive heart failure (HF).1–3 The
pathological hallmarks of ARVC are progressive loss of
cardiomyocytes and fibrofatty infiltration from epicardial to
endocardial.4,5 Pathogenic mutations in genes encoding des-
mosomal proteins account for ~50% of ARVC patients, but
at least 10 other genes have also been implicated in this dis-
ease, such as PLN, DES, LMNA, and TMEM43.2,6
Patients with ARVC can be clinically quiescent, with occa-
sional periods of flares involving increased arrhythmic activi-
ties, also known as hot phases.2,7 The most important
objective in the management of ARVC patients was preven-
tion of disease exacerbations for it puts the patients at high
risk of sudden cardiac death (SCD).2 Nowadays, as implant-
able cardioverter defibrillators (ICD) proved to be useful for
the prevention of SCD in ARVC, the remodelling of the cardiac
structure and progressive heart failure is becoming other es-
sential threats for disease prognosis.8 However, there has
been little attention focused on the ventricular dysfunction
progress in ARVC.7 A transatlantic cohort provided definitive
evidence, revealing that structural progression was also
found to be associated with adverse outcomes in ARVC.9,10
Depending on the trend of disease progression (the abnor-
malities of electrophysiology or ventricular dysfunction pro-
gression), different treatments should be taken to achieve
good clinical efficacy. Thus, it is necessary to identify risk pre-
dictors that could specifically predict the patients susceptible
to adverse HF events or malignant arrhythmic events during
the study’s follow-up period. Clinically, risk stratification in
ARVC mainly depends on the measurement of structural dys-
function detected by cardiac imaging and electrocardiogram
findings.11 Besides, some genetic or molecular indicators
were also found helpful for diagnosis or risk stratification.
Some desmosomal mutations such as plakophilin-2 (PKP2)
and desmoplakin (DSP) mutations were also known to be as-
sociated with poor clinical outcomes.9,12
Also, plasma anti-DSG2 antibodies showed a high specific-
ity and sensitivity for the diagnosis of ARVC.13 Moreover,
ARVC patients with higher plasma levels of
pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) had
higher arrhythmic risks.14 Likewise, other biomarkers such
as plasma bridging integrator 1 (BIN1),15 galectin-3,16 BNP17
and C-reactive protein (CRP)18 levels also indicated increased
risks of arrhythmic events in ARVC patients. Nevertheless, af-
fected by other complications such as heart failure, these
established markers are not specific for predicting arrhythmic
outcomes. Hence, in consideration of the ambiguous status
of these biomarkers in outcome discrimination and few re-
ported multicentre validation, new biomarkers pinpointing
particular outcome of AVRC and contributing to clear risk
stratification are also necessary. Recently, promising evidence
suggested that sex hormones, in particular testosterone, may
play an essential role in predicting arrhythmic risk in ARVC.19
Testosterone is the principal male sex hormone and circu-
lates in the blood mostly bound to sex hormone-binding glob-
ulin (SHBG) or albumin, with only a small fraction in a free
form. Epidemiological studies suggested that high levels of
testosterone could exacerbate heart failure symptoms in pa-
tients with systolic dysfunction.20 Animal studies also showed
that high testosterone levels were associated with increased
arrhythmic risk.21,22 In ARVC patients, elevated testosterone
levels were evidenced to be valuable predictors for adverse
arrhythmic outcomes.19 Nevertheless, publications clarifying
role of testosterone in ARVC outcomes are limited yet, and
the relationship between testosterone levels and cardiac dys-
function in ARVC is still obscure. Therefore, we investigated
the reproducibility of these findings by studying the role of
testosterone in predicting major arrhythmic events in the Chi-
nese ARVC cohort and further explored the role of this hor-
mone in predicting cardiac structural progression.
Methods
Study population and clinical data collection
The following formulas are used to calculate the sample size
and power, respectively.23
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where κ = nA/nB is the matching ratio, σ is a standard devia-
tion, Φ is the standard normal distribution function, α is Type
I error, β is Type II error. When the 1  β (power) was set to
0.9, α was 2.5%, κ was 1, the nAC male and nnormal male was cal-
culated to be 60.
Ninety-nine AC patients (68 male) and 96 healthy volun-
teers (61 male) were selected from the Chinese ARVC cohort
by stratified random sampling. Between October 2015 and
July 2018, 118 (81 men) unrelated probands diagnosed with
ARVC 24 were included in the Chinese ARVC cohort. The ARVC
diagnosis was made according to the 2010 revised Task Force
Criteria and confirmed by cardiologist and radiologist through
the medical history, histological examination, and clinical
1548 J. Ren et al.
ESC Heart Failure 2020; 7: 1547–1559
DOI: 10.1002/ehf2.12704
examination including echocardiography, ECG, CMR, and 24 h
Holter. All the ARVC probands were of Chinese Han
nationality.
Supporting Information, Table S1 shows the details of the
2010 Revised Task Force Criteria of the 68 male ARVC pa-
tients, which relied on the demonstration of structural, func-
tional, and electrophysiological abnormalities. Given physical
exercise could promote both structural progression and ar-
rhythmic events in ARVC,2 we excluded ARVC patients or
healthy volunteers with competitive or endurance sport ac-
tivity to avoid introducing associated cofounding factors. This
made the physical activity levels between ARVC patients and
control approximate comparable.
The control subjects did not have history of heart disease,
hypertension, or metabolic disease. All patients underwent
measurements of circulating levels of testosterone. The base-
line demographics and medical details of ARVC patients were
obtained retrospectively from patient charts at blood with-
drawal and during follow-up by investigators blinded to the
assay results. The follow-up started from blood collection
and came to an end with observations of clinical endpoint
events. Malignant arrhythmic events were defined as SCD,
survived SCD, ventricular fibrillation (VF), sustained ventricu-
lar tachycardia (VT), and appropriate ICD discharge. ARVC pa-
tients with ventricular dysfunction had a high probability of
undergoing heart transplantation or death during follow-up
in the Fuwai cohort;7 therefore, according to the previous
literature,8 we defined the significant structural progression
event (SSPE) as a numerical reduction of 10% in LVEF based
on echocardiography, heart transplantation, or death due to
end-stage heart failure. The patients were followed-up for a
median of 17 (interquartile ranges, IQR) months9–29 in order
to assess the role of plasma testosterone in survival outcome
stratification. This study was approved by the Ethics Commit-
tee of Fuwai Hospital, Beijing, China. All patients provided
written informed consent.
Measurements of plasma testosterone levels
For each hospitalized patient or outpatient, peripheral ve-
nous blood was collected in pyrogen-free EDTA tubes be-
tween 7 a.m. and 10 a.m. before they took heavy
medication. The blood samples were immediately centrifuged
at 2000 g for 20 min at 4°C to separate the plasmas and were
stored at 80°C until assayed. Enzyme-linked immunosor-
bent assays (ELISA) were used to measure circulating levels
of total testosterone (KGE010, R&D Systems, USA), SHBG
(DSHBG0B, R&D Systems, USA), and albumin (EHALB,
Thermo, UK) in plasma. All tests were performed according
to the manufacturers’ protocols. The free and bioavailable
testosterone levels were measured using the calculator at
http://www.issam.ch/freetesto.htm. The coefficient of varia-
tion (CV) values of the total testosterone, SHBG, and albumin
essays were 5.6%, 7.6%, and 8.8%, respectively. And the limit
of detection (LoD) was 0.041 ng/mL, 0.1 nmol/L, and 4.92 ng/
mL, respectively.
Genetic screening
The whole-genome DNA was extracted from peripheral blood
cells of ARVC patients using the DNeasy Blood and Tissue Kit
(Qiagen, USA). Targeted next-generation sequencing was per-
formed based on the Illumina Hi-seq2000 platform (Illumina,
USA). The pathogenicity of the variant was filtered and eval-
uated by ACMG guidelines, and the mutations were identified
as pathogenic, likely pathogenic, or a variant of uncertain sig-
nificance (VUS); details were previously described.25
Statistical analysis
Continuous variables were expressed as the median with IQR,
and categorical variables were presented as numbers and
percentages. Categorical variables were analysed by χ2 tests
or Fisher’s exact test. For continuous variables, the Mann–
Whitney U test was used for comparisons between two
groups, and the Kruskal–Wallis test was used for multiple
groups (≥three groups, each P value is adjusted to account
for the Dunn’s multiple comparisons test). The correlations
between testosterone level and clinical variables were
analysed by Spearman’s analysis. Malignant arrhythmic
events-free survival rates were estimated by Kaplan–Meier
curves and compared by the log-rank test. Cox proportional
hazards regression was used to analyse the effect of plasma
testosterone and other well-described risk factors on malig-
nant arrhythmic events in male ARVC patients. Variables with
significance level <0.1 were included in multivariate model.
All statistical analyses were performed using SPSS Statistics,
version 23.0 (IBM Corp, Armonk, NY, USA). Statistical charts
were plotted using GraphPad Prism 7 (GraphPad Software
Inc., CA, USA). A covariate with P < 0.05 was considered
significant.
Results
Baseline characteristics and circulating
testosterone
The clinical characteristics of the study population are pre-
sented in Table 1. At the time of blood collection, 44.79%
of ARVC patients had suffered malignant arrhythmic events
in medical history since onset of the disease. LV dysfunction,
defined as LV ejection fraction (LVEF) < 50% by echocardiog-
raphy, was rather common (34.34%), indicating advanced
stages of disease in our ARVC cohort. The plasma levels of
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Table 1 Baseline characteristics and the testosterone level of patients with ARVC and controls (N = 195)
Characteristics ARVC (N = 99) Control (N = 96) P value
Male (%) 68/99 (70.7%) 61/96 (62.5%) 0.4543
Age (year) 40 (30–52) 41 (30–52) 0.3838
Weight (kg) 64 (55.5–75.0) 70 (60.0–77.0) 0.2857
Height (cm) 170 (164.3–175.0) 170 (165.0–175.0) 0.8140
Body mass index (kg/m
2
) 22.76 (20.42–25.27) 23.83 (20.76–25.71) 0.1619
Systolic pressure (mmHg) 113 (100.0–124.3)
Diastolic pressure (mmHg) 70 (64.25–80.00)
MAE at baseline (%) 43/96 (44.79%)
Age at onset of arrhythmia 27 (22.0–38.5)
Diabetes 5/87 (5.75%)
Hypertention 7/88 (7.95%)
Smoking history 19/87 (21.84%)
History of alcohol 18/87 (20.69%)
IVS (mm) 9.0 (8.0–10.0) 8.3 (7.0–9.6) 0.1158
RVEDD (mm) 34.5 (26.75–44.25) 22.9 (20.70–24.60) <0.0001
LVEDD (mm) 48.0 (45.0–55.0) 46.6 (45.1–48.4) 0.1379
LVEF (%) 51.50 (40.00–61.25) 60.75 (55.21–66.21) 0.0225
RVEF (%) (by CMR) 18 (12.5–27.0)
NYHA
I (%) 37/96 (38.54%)
II (%) 19/96 (19.79%)
III (%) 20/96 (20.83%)
IV (%) 18/96 (18.75%)
Epsilon waves (%) 12/53 (22.64%) 0/41 0.0009
QRS fragmentation (%) 37/53 (69.81%) 0/41 <0.0001
Negative T waves (%) 39/53 (73.58%) 1/41 (2.44%) <0.0001
Medication
ACEI/ARB (%) 41/83 (49.40%)
Beta-blockers (%) 65/87 (74.71%)
Spirolactone (%) 52/82 (63.41%)
Amiodarone (%) 23/78 (29.49%)
Glucose (mmol/L) 4.72 (4.310–5.075)
HbAlc (%) 5.7 (5.3–6.3)
Albumin (g/L) 43.5 (39.75–45.85)
AST (IU/L) 20.5 (16–29)
ALT (IU/L) 23 (16.00–29.25)
Creatinine (μmol/L) 80 (68.30–90.78)
BUN (mmol/L) 5.61 (4.508–6.925)
Triglyceride (mmol/L) 1.105 (0.80–1.64)
Cholesterol (mmol/L) 3.95 (3.17–4.57)
NT-proBNP (pg/mL) 613.4 (304.7–2086.0)
CK (IU/L) 71 (55.0–106.5)
CK-MB (ng/mL) 10 (8–15)
cTnI (ng/mL) 0.03 (0.0075–0.0870)
Hs-CRP (mg/L) 1.295 (0.5425–2.7930)
Big-ET (pmol/L) 0.53 (0.240–0.818)
SHBG (nmol/L) 22.16 (10.54–41.31) 35.67 (21.03–54.42) 0.0785
Total testosterone (TT) (ng/mL) 4.622 (0.467–7.433) 1.988 (0.201–4.024) <0.0001
TT in male (Dunn’s multiple comprison) 6.390 (4.438–8.768) 3.617 (2.073–4.479) <0.0001
TT in female (Dunn’s multiple comprison) 0.3166 (0.1412–0.4392) 0.1359 (0.0514–0.2634) >0.9999
Free testosterone (FT) (ng/mL) 0.106 (0.0134–0.271) 0.0400 (0.0032–0.0918) <0.0001
FT in male (Dunn’s multiple comprison) 0.2055 (0.1000–0.4073) 0.0768 (0.0405–0.1105) <0.0001
FT in female (Dunn’s multiple comprison) 0.0036 (0.0021–0.0125) 0.0018 (0.0008–0.0045) >0.9999
Per cent of FT (%) 2.69 (1.44–4.12) 1.81 (1.41–2.573) 0.0012
Bioavailable testosterone (BT) (ng/mL) 2.21 (0.239–5.480) 0.7395 (0.0766–1.6280) <0.0001
BT in male (Dunn’s multiple comprison) 4.11 (1.990–6.545) 1.32 (0.7965–2.0350) <0.0001
BT in female (Dunn’s multiple comprison) 0.123 (0.0309–0.2370) 0.0412 (0.0162–0.0868) >0.9999
Per cent of BT (%) 59.4 (36.5–77.5) 41.45 (24.63–57.88) <0.0001
Data are expressed as median (IQR) or as number (percentage). For testosterone, 1 ng/mL = 3.467 nmol/L. Mann–Whitney test was used
for comparison of continuous variables and Fisher’s exact test for categorical variables. P values <0.05 were considered significant.
ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blockers; ALT, alanine aminotransferase; ARVC, arrhythmogenic
right ventricular cardiomyopathy; AST, aspartate aminotransferase; Big-ET, big-endothelin; BUN, blood urea nitrogen; CK-MB, creatine ki-
nase isoenzyme; CTnI, cardiac troponin I; HbAlc, glycosylated haemoglobin; Hs-CRP, high-sensitivity C-reactive protein; IVS, interventric-
ular septal thickness; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MAE, malignant arrhythmic
events; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; RVEDD, right ventricular end-diastolic
diameter; RVEF, right ventricular ejection fraction; SHBG, sex hormone-binding globulin.
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total testosterone (TT) [4.622 (0.467–7.433) vs. 1.988 (0.201–
4.024), P< 0.0001, data expressed as median (IQR)], free tes-
tosterone (FT) [0.106 (0.0134–0.271) vs. 0.106 (0.0134–
0.271), P < 0.0001, median with IQR], and bioavailable tes-
tosterone (BT) [2.21 (0.239–5.480) vs. 0.7395 (0.0766–
1.6280), P < 0.0001, median with IQR] in ARVC patients were
significantly higher as compared with those measured in
healthy volunteers (Table 1). Although the sample size of nor-
mal controls was small, the normal value range for testoster-
one was consistent with previous reports.26,27
As shown in Figure 1 and Table 1, significant deviations of
TT, FT, and BT were between different genders. To exclude
the effects of gender, a subgroup comparison was performed
within female and male participants. The plasma concentra-
tions of TT and BT had significant differences between the
ARVC patients and healthy volunteers among male probands,
whereas no differences were observed between patients and
healthy subjects in female counterparts (Figure 1). Further-
more, we compared the testosterone levels among male pa-
tients with different genotypes. A majority of male patients
(50/68) were genotype positive (Supporting Information, Ta-
ble S1), including 11 patients with desmoglein-2 (DSG2), 10
patients with PKP2, 4 with DSP, 3 with desmocollin-2 (DSC2)
mutations, and 1 with plakoglobin (JUP) mutation. Eight pa-
tients had more than one pathogenic variant (at least one
desmosomal mutation each). The Kruskal–Wallis test showed
that the levels of TT and BT had no significant association
with the underlying genetic mutation. (Figure 2A and
Supporting Information, Figure S1A).
Correlation analysis of testosterone in male ARVC
patients.
The correlation analysis revealed that neither ventricular dila-
tion (LV/RV end-diastolic diameters) nor cardiac dysfunction
(LVEF, RVEF, and New York Heart Association class) at base-
line had any association with TT or BT levels (Table 2, Figure
2B, Supporting Information, Figure S1B). These results sug-
gested that testosterone levels were not indicative of cardiac
structural or functional remodelling. There was no correlation
between the baseline malignant arrhythmic events and tes-
tosterone levels. There were no significant correlations be-
tween testosterone levels and indices of hepatorenal
function such as alanine aminotransferase, aspartate amino-
transferase, blood urea nitrogen, and creatinine. Likewise,
testosterone levels were not related to the inflammatory fac-
tors, high-sensitivity C-reactive protein, and cardiac troponin
T (Table 2). Some medications, such as amiodarone,
spironolactone, and beta-blockers, have been reported to
have an association with testosterone levels.28,29 But our
analysis (Figure 2C–I and Supporting Information, Figure
S1C,D) demonstrated that there was no significant difference
between the groups with or without drug use, cardiovascular
Figure 1 Plasma testosterone levels between the ARVC patients and healthy. The average level of testosterone in the female group was significantly
lower than that of the male. The concentrations of plasma total testosterone (TT) and bioavailable testosterone (BT) had a significant difference be-








P < 0.0001 using Kruskal–Wallis test, and each P value is adjusted to account for the Dunn’s multiple comparisons test).
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risk factors (smoking, alcohol, etc.), and co-morbidities (dia-
betes, hypertension, etc.).
Circulating testosterone predicting malignant
arrhythmic events
To evaluate the role of testosterone levels in predicting clini-
cal adverse arrhythmic events, we performed a follow-up
study among 68 ARVC male patients. During 17 months9–29
of follow-up, 5 were withdrawn, 16 patients experienced
SSPE, and 22 developed malignant arrhythmic events (Table
3). Amid two patients with both malignant arrhythmic events
and SSPE, plasma testosterone levels (TT = 6.05 ng/mL,
4.90 ng/mL separately) were significantly lower than the av-
erage level in malignant arrhythmic events (TT = 11.73 ng/
mL)—but were more similar with the expression levels in
SSPE—and we included these patients in the malignant ar-
rhythmic events group. The plasma levels of TT, BT, and FT
in patients who experienced malignant arrhythmic events
Figure 2 The association between TT levels and the baseline characteristics of the ARVC male patients (N = 68). (A) Genetic mutation status of male AC
patients (n = 68). The plasma testosterone levels had no significant association with the underlying genetic mutation in male AC patients (using the
Kruskal–Wallis test). (B) There was no significant difference in testosterone levels among groups with different NYHA. And the levels of testosterone
also had no association with the baseline characteristics of the ARVC male patients, including the cardiovascular risk factors (C), co-morbidities (D), and
heart failure medications (E–I).
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were higher than those without (P value was adjusted by
Dunn’s multiple comparisons test) (Figure 3). It is worth not-
ing that the concentrations of testosterones negatively corre-
lated with follow-up time (Supporting Information, Figure S2),
indicating that testosterone might be a predictor for
malignant arrhythmic events. Sixteen patients had isolated
SSPE, including 10 patients with transplants, 2 who died,
and 4 with a numerical decrease over 10% in LVEF, but they
did not have significantly higher plasma testosterone levels
(Figure 3). Consistent with previous studies, our results indi-
cate that arrhythmias and cardiac structural progression are
different disease processes, even during initial short-time
follow-up.8 The results of Swiss cohort, with a different ethnic
group, also proved that the testosterone level was associated
with major arrhythmic cardiovascular events.19 The similar
conclusions within the Swiss cohort expanded the applicable
population of this discovery.
The clinical characteristics of the ARVC male patients with
malignant arrhythmic events, SSPE, and non-event groups
Table 2 Testosterone correlation with clinical characteristics in male ARVC patients (N = 68)
Variables
Spearman correlation (TT) Spearman correlation (BT)
ρ P value ρ P value
Height (cm) 0.315 0.013 0.327 0.010
Weight (kg) 0.125 0.343 0.112 0.393
Body mass index (kg/m
2
) 0.032 0.801 0.001 0.991
Age (year) 0.066 0.603 0.119 0.345
Systolic pressure (mmHg) 0.054 0.668 0.078 0.535
Diastolic pressure (mmHg) 0.030 0.815 0.001 0.995
Heart rate (per min) 0.082 0.518 0.110 0.381
Age at onset of heart disease (year) 0.157 0.230 0.209 0.108
Age at onset of arrhythmia (year) 0.050 0.717 0.142 0.307
Length of drinking history (year) 0.160 0.585 0.197 0.500
Length of smoking history (year) 0.062 0.800 0.066 0.789
Number of precordial TWI 0.032 0.855 0.185 0.287
Number of precordial QRS fragmentation 0.046 0.792 0.116 0.506
LAID (mm) 0.011 0.931 0.055 0.668
IVS (mm) 0.008 0.951 0.056 0.659
LVEDD (mm) 0.169 0.177 0.028 0.822
LVEF (%) 0.100 0.430 0.048 0.706
RVEDD (mm) 0.038 0.765 0.045 0.722
RVEF (%) (by CMR) 0.099 0.631 0.077 0.709
Hb (g/L) 0.091 0.490 0.112 0.396
Albumin (g/L) 0.141 0.269 0.001 0.998
Glucose (mmol/L) 0.020 0.879 0.078 0.550
HbAlc (%) 0.163 0.267 0.171 0.245
AST (IU/L) 0.005 0.971 0.057 0.660
ALT (IU/L) 0.016 0.905 0.073 0.571
P (mmol/L) 0.273 0.037 0.260 0.047
Ca (mmol/L) 0.074 0.578 0.048 0.716
Creatinine (μmol/L) 0.066 0.608 0.126 0.329
BUN (mmol/L) 0.050 0.702 0.055 0.671
Triglyceride (mmol/L) 0.001 0.992 0.092 0.486
Cholesterol (mmol/L) 0.194 0.134 0.041 0.756
LDL-Chol (mmol/L) 0.153 0.248 0.070 0.599
HDL-Chol (mmol/L) 0.100 0.457 0.045 0.737
FFA (mmol/L) 0.129 0.378 0.127 0.386
LP(a) (mg/L) 0.046 0.731 0.100 0.456
Apo A1 (g/L) 0.121 0.399 0.031 0.827
cTnI (ng/mL) 0.064 0.771 0.202 0.356
Hs-CRP (mg/L) 0.147 0.261 0.207 0.113
NT-proBNP (pg/mL) 0.122 0.367 0.131 0.333
ALT, alanine aminotransferase; ARVC, arrhythmogenic right ventricular cardiomyopathy; AST, aspartate aminotransferase; BT, bioavailable
testosterone; BUN, blood urea nitrogen; Ca, blood calcium; cTnI, cardiac troponin I; FFA, free fatty acid; Hb, haemoglobin; HbAlc, glyco-
sylated haemoglobin; HDL-Chol, high density lipoprotein cholesterol; Hs-CRP, high-sensitivity C-reactive protein; IVS, interventricular sep-
tal thickness; LAID, left atrium internal dimension; LDL-Chol, low density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic
diameter; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; P, blood phosphorus; RVEDD, right
ventricular end-diastolic diameter; TT, total testosterone; TWI, T wave inversion.
Table 3 The distribution of malignant arrhythmic events
Malignant arrhythmic events N = 22
Survived sudden cardiac arrest, n (%) 1 (4.55)
Sustained ventricular tachycardia, n (%) 11 (50.00)
appropriate ICD discharge, n (%) 10 (45.45)
Malignant arrhythmic events were defined as SCD, survived SCD,
sustained ventricular tachycardia (VT), or appropriate ICD
discharge.
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are presented in Table 4. Baseline characteristics and clinical
data were roughly comparable among the groups, except
for cardiac function (SSPE had worse HF symptoms). We ob-
served that plasma testosterone level predicted a high risk
of arrhythmia but not the SSPE for ARVC male patients. To
further validate the relationship between plasma testoster-
one and arrhythmic events in male ARVC patients, we applied
the receiver operating characteristic curve (ROC) to reveal
the optimum cut-off value for TT, BT, and FT in discriminating
malignant arrhythmic events positive and negative groups
(TT = 6.722 ng/mL, AUCTT = 0.902; BT = 4.650 ng/mL, AUC-
BT = 0.803; FT = 0.257 ng/mL, AUCFT = 0.794) (Figure 4A–C).
By using the cut-off value as a grouping condition, it was
demonstrated that there was a significant difference in malig-
nant arrhythmic events-free survival rates between the
groups (log-rank pTT<0.0001; log-rank pBT<0.0001; log-rank
pFT<0.0001) (Figure 4D–F).
For the male ARVC patients (n = 68), we further applied the
Cox regression models to determine whether testosterone
levels were associated with malignant arrhythmic events in-
dependently. Because all covariates reported in Table 2 were
insignificant, we included several clinically relevant variables
that were directly or indirectly relevant to testosterone con-
centrations into the Cox model.30,31 Given the highest AUC
value (AUCTT = 0.9024) of TT to malignant arrhythmic events,
and the strong correlation among the expression levels of TT,
FT, and BT (Pearson correlation, rTT  FT = 0.727, p-
TT  FT<0.001; rTT  BT = 0.889, pTT  BT < 0.001), we only in-
cluded the TT into Cox regression analysis to eliminate
collinearity. Based on the result of the multivariate Cox re-
gression model, plasma TT level (HR = 1.325, 95% CI [1.171,
1.498]) was identified as an independent prognostic factor
for malignant arrhythmic events (Table 5).
Discussion
In this study, we found that elevated levels of plasma testos-
terone are strong predictors of future adverse arrhythmic
events in male patients with ARVC, supporting the hypothe-
sis that sex hormone may play a role in the pathophysiology
of the disease. Our findings in the Chinese ARVC cohort with
a different genetic and race background and distinct base-
line data are in line with previous observations reported by
Akdis et al.19 Furthermore, we also have several novel
findings1: ARVC male patients showed higher levels of tes-
tosterone than normal males, while female counterparts
did not.2 The testosterone levels were not related to base-
line cardiac function and future significant structural pro-
gression event but served as an independent predictor
arrhythmia event.
Arrhythmogenic right ventricular cardiomyopathy may
be associated with life-threatening ventricular arrhythmias
in both early stage and subsequent progressive biventricular
systolic dysfunction. Therefore, disease management
should not only focus on the prevention and therapy of ar-
rhythmias but also on halting or slowing down the progres-
sion of structural remodelling, in order to prevent
heart failure.9 Previous researches were committed to pre-
dict arrhythmic prognosis among ARVC patients based on
imaging parameters or genotype testing.11,32 Our study ver-
ified a new biomarker that can independently predict ar-
rhythmia risk events in ARVC male patients without the
influence of cardiac insufficiency or other factors,
providing a new method for the prognosis assessment of
ARVC male patients. Our ARVC cohort was considerably dif-
ferent from the previous Swiss cohort.19 The Swiss cohort
mainly consisted of ARVC patients with arrhythmias at an
early or intermediate stage, while our cohort mainly en-
rolled ARVC patients at the advanced or terminal stage. It
is reasonable that more severe phenotypes were
observed in our ARVC cohort. In fact, as the National Cen-
tre for Cardiovascular Disease in China, Fuwai Hospital is
also the biggest designated hospital for heart transplanta-
tion (more than 100 heart transplantations were performed
annually in Fuwai). Hence, we have many referral patients
from other hospitals, some of whom were in serious condi-
tion and required heart transplant. The blood testosterone
can have high prediction efficiencies in both cohorts,
Figure 3 Circulating testosterone levels are associated with malignant arrhythmic events (MAE) in the follow-up. Plasma testosterone levels are sig-
nificantly elevated in ARVC male patients with malignant arrhythmic events using the Kruskal–Wallis U test, whereas patients with significant structural
progression event (SSPE) did not have significantly higher plasma testosterone levels (P values adjusted by Dunn’s multiple comparisons test).
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indicating its arrhythmia risk predictive ability for patients
with ARVC in a different spectrum. The consistent high pre-
diction efficiency of plasma testosterone in both Chinese
and Swiss cohort revealed that testosterone could be a sta-
ble predictor for arrhythmia in ARVC patients despite racial
differences.
It remains unclear why plasma testosterone levels are
higher in ARVC male patients with severe arrhythmic events.
We speculated that the ARVC patients with malignant ar-
rhythmic events were in a state of more severe stress that
promoted adrenal hormones secretion. Testosterone could
exacerbate cardiomyocyte apoptosis and ion channels dys-
function. By using an ARVC patient-derived iPSC-
cardiomyocyte model, it was demonstrated that testoster-
one could accelerate cardiomyocyte apoptosis and lipid ac-
cumulation due to defective canonical Wnt signalling
pathway, which may be triggered by the abnormal activation
of peroxisome proliferator-activated receptor-gamma
(PPARγ) signalling.33 By contrast, the testosterone did not in-
tensify the lipogenesis and apoptosis in the healthy iPSC-
CMs.19 These results indicate that testosterone could specif-
ically worsen those pathologies prompting the arrhythmic
potential in ARVC.
Arrhythmogenic right ventricular cardiomyopathy, unlike
other SCD-related diseases, has pathological hallmarks of
progressive cardiomyocytes loss and fibrofatty infiltration.
In a community-based study, Kumar Narayanan et al. found
that higher testosterone levels were associated with lower
sudden cardiac arrest in males.34 This was probably because
testosterone can also cause malignant clinical events by af-
fecting ion channels. The testosterone-treated
cardiomyocytes had higher androgen and β1-adrenergic re-
ceptor expressions that result in longer corrected QT
intervals.21 Moreover, some studies focused on the influ-
ences of testosterone on the myocardial contractile function
regulated by Ca2+ handling. It was shown that testosterone
modified the inward peak T-type Ca2+ currents, leading to
prolonged depolarization, so that it may play a key role in
the pathogenesis of many cardiovascular diseases.35 It can
be inferred that testosterone might participate in electro-
physiological dysfunction and disease pathogenesis. And
the influence of elevated testosterone in ARVC remains to
be further elucidated.
We have to acknowledge that our study is limited by
the fact that testosterone levels may show biological
variability in the short-term and long-term. Moreover, even
though all ARVC patients received standard
treatment, given the limitations of sample size, we did
not take the therapeutic drugs into account. We were also
unable to adjust for all possible confounding variables re-
lated to the outcome. Additional investigations from
multicentre cohorts are required for further validating the
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Conclusions
Plasma testosterone levels were higher in ARVC male patients
than in those measured in healthy male patients and can pre-
dict future adverse arrhythmic events in male patients with
ARVC but also not concerned with baseline cardiac function
and follow-up SSPE. And similar results between the Chinses
Hans and Caucasians expanded the applicable population of
this discovery. Therefore, our results suggested that
testosterone may be a promising biomarker in arrhythmic risk
prediction in the ARVC.
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Table 5 Increasing serum testosterone is an independent predictor of malignant arrhythmic events in male ARVC patients (Cox regression
analysis)
Variables
Univariate Analysis Multivariate Analysis
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BMI 1.122 (0.997–1.263) 0.057 1.086 (0.921–1.280) 0.327
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MAE at baseline 3.448 (1.339–8.875) 0.010 1.448 (0.378–5.544) 0.589
LVEF% 1.00 (0.97–1.04) 0.836
NYHA 0.787 (0.452–1.370) 0.397
TWI 0.998 (0.776–1.282) 0.986
NSVT 4.429 (0.595–32.969) 0.146
RVEF (CMR) 0.984 (0.941–1.029) 0.471
NT-proBNP 1.000 (1.000–1.001) 0.593
CK-MB 0.880 (0.777–0.997) 0.044 0.826 (0.671–1.016) 0.070
CTnI 1.188 (0.816–1.729) 0.368
Hs-CRP 0.976 (0.804–1.185) 0.808
Beta-blockers 1.805 (0.420–7.764) 0.427
Amiodarone 2.180 (0.897–5.298) 0.085 1.497 (0.509–4.406) 0.464
Spironolactone 1.150 (0.487–2.712) 0.750
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Table S1. Clinical diagnosis of ARVC male patients (n = 68)
based on Task Force Criteria in 2010
Table S2. Baseline characteristics of ARVC patients between
Swiss and China cohort.
Figure S1. The levels of BT and FT were not affected by the baseline
characteristics of ARVC male patients. A. there was no significant dif-
ference of BT and FT among the different types of mutations. B-D.
The levels of BT and FT had no association with the baseline charac-
teristics of the ARVC patients, including the cardiac function (B), car-
diovascular risk factors (C) and heart failure medications (D).
Figure S2. The rate of malignant arrhythmic events was line with
concentration of testosterones. A-C. The concentrations of testoster-
ones held a negative relationship with follow-up time. The higher
levels of testosterones predict the malignant arrhythmic events will
become more soon.
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